Lorenza Rimassa
@lorenzarimassa.bsky.social
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma
Reposted by Lorenza Rimassa
🤖 How can generative and foundation models reshape oncology, - from research to clinical practice?
Find out in the session “Generative AI” at #ESMOAI25 in Berlin.
👉 www.esmo.org/meeting-cale...
Find out in the session “Generative AI” at #ESMOAI25 in Berlin.
👉 www.esmo.org/meeting-cale...
October 25, 2025 at 6:17 AM
🤖 How can generative and foundation models reshape oncology, - from research to clinical practice?
Find out in the session “Generative AI” at #ESMOAI25 in Berlin.
👉 www.esmo.org/meeting-cale...
Find out in the session “Generative AI” at #ESMOAI25 in Berlin.
👉 www.esmo.org/meeting-cale...
JulieHeimbach discusses #livertransplant for patients with intrahepatic or perihilar #cholangiocarcinoma #CCA at the Advances in Hepatology Symposium in Berlin #FalkFoundation
October 25, 2025 at 10:03 AM
JulieHeimbach discusses #livertransplant for patients with intrahepatic or perihilar #cholangiocarcinoma #CCA at the Advances in Hepatology Symposium in Berlin #FalkFoundation
Reposted by Lorenza Rimassa
🎥 50 years of key moments.
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
October 19, 2025 at 1:49 PM
🎥 50 years of key moments.
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
@myesmo.bsky.social is where everything began, my first international oral presentation as a resident in medical oncology, my first international role as chair, discussant, invited speaker.
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
October 20, 2025 at 9:53 AM
@myesmo.bsky.social is where everything began, my first international oral presentation as a resident in medical oncology, my first international role as chair, discussant, invited speaker.
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
It’s great to see a friend and colleague growing within @myesmo.bsky.social!
#ESMO25
#myESMOStory
#ESMOAmbassadors
#ESMO25
#myESMOStory
#ESMOAmbassadors
October 20, 2025 at 9:45 AM
It’s great to see a friend and colleague growing within @myesmo.bsky.social!
#ESMO25
#myESMOStory
#ESMOAmbassadors
#ESMO25
#myESMOStory
#ESMOAmbassadors
James Harding presents phase 1 data showing a manageable safety profile and promising efficacy in advanced #PDAC at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:49 AM
James Harding presents phase 1 data showing a manageable safety profile and promising efficacy in advanced #PDAC at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Reposted by Lorenza Rimassa
🎉 Your #myESMOStory moments made ESMO’s 50th anniversary special.
From selfies at #ESMO25 to memories shared from afar, together we marked 50 years of progress in oncology.
Here’s to accelerating impact! #ONEoncologycommunity
From selfies at #ESMO25 to memories shared from afar, together we marked 50 years of progress in oncology.
Here’s to accelerating impact! #ONEoncologycommunity
October 20, 2025 at 7:43 AM
🎉 Your #myESMOStory moments made ESMO’s 50th anniversary special.
From selfies at #ESMO25 to memories shared from afar, together we marked 50 years of progress in oncology.
Here’s to accelerating impact! #ONEoncologycommunity
From selfies at #ESMO25 to memories shared from afar, together we marked 50 years of progress in oncology.
Here’s to accelerating impact! #ONEoncologycommunity
Do-Youn Oh discusses abstracts on #biliary tract cancer #BTC #CCA orally presented at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:44 AM
Do-Youn Oh discusses abstracts on #biliary tract cancer #BTC #CCA orally presented at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Michele Reni presents novel findings from the #CASSANDRA phase 3 study of perioperative treatment in #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:34 AM
Michele Reni presents novel findings from the #CASSANDRA phase 3 study of perioperative treatment in #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
IMMUNOBIL phase 2 study of immunotherapy #STRIDE for patients with previously treated advanced #BTC #CCA. Negative study but a subgroup of patients seem to benefit, we need biomarkers.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:26 AM
IMMUNOBIL phase 2 study of immunotherapy #STRIDE for patients with previously treated advanced #BTC #CCA. Negative study but a subgroup of patients seem to benefit, we need biomarkers.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Phase 2-3 ZSAB-neoGOLP trial of #neoadjuvant GOLP regimen for resectable i#CCA with high-risk features for recurrence. A positive interim analysis, but not a standard regimen. Novel approaches are needed.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:18 AM
Phase 2-3 ZSAB-neoGOLP trial of #neoadjuvant GOLP regimen for resectable i#CCA with high-risk features for recurrence. A positive interim analysis, but not a standard regimen. Novel approaches are needed.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Milind Javle presents the results of #tinengotinib in patients with #CCA #BTC and #FGFR2 gene fusions previously treated with other FGFR inhibitors at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:13 AM
Milind Javle presents the results of #tinengotinib in patients with #CCA #BTC and #FGFR2 gene fusions previously treated with other FGFR inhibitors at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
@arndtvogel.bsky.social discusses #ABC-HCC and #TALENTop studies and puts them into the context.
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 6:56 AM
@arndtvogel.bsky.social discusses #ABC-HCC and #TALENTop studies and puts them into the context.
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Hui-Chuan Sun presents the #TALENTop phase 3 study of atezolizumab-bevacizumab followed by surgery in locally advanced #HCC.
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 6:49 AM
Hui-Chuan Sun presents the #TALENTop phase 3 study of atezolizumab-bevacizumab followed by surgery in locally advanced #HCC.
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Peter Galle presents ABC-HCC, academic study of atezolizumab-bevacizumab vs TACE for intermediate stage #HCC.
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 6:41 AM
Peter Galle presents ABC-HCC, academic study of atezolizumab-bevacizumab vs TACE for intermediate stage #HCC.
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Interested in or worried about #LargeLanguageModels in #ClinicalPractice? The @myesmo.bsky.social Guidance (#ELCAP) is out and ready for download!
#ESMO25 #ESMOAmbassadors
#ESMO25 #ESMOAmbassadors
The ESMO Guidance on the use of #LargeLanguageModels in #ClinicalPractice (#ELCAP) is out: the first structured set of recommendations to bring #AI language models into #oncology safely and effectively.
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
October 19, 2025 at 12:35 PM
Interested in or worried about #LargeLanguageModels in #ClinicalPractice? The @myesmo.bsky.social Guidance (#ELCAP) is out and ready for download!
#ESMO25 #ESMOAmbassadors
#ESMO25 #ESMOAmbassadors
Reposted by Lorenza Rimassa
The ESMO Guidance on the use of #LargeLanguageModels in #ClinicalPractice (#ELCAP) is out: the first structured set of recommendations to bring #AI language models into #oncology safely and effectively.
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
October 19, 2025 at 7:45 AM
The ESMO Guidance on the use of #LargeLanguageModels in #ClinicalPractice (#ELCAP) is out: the first structured set of recommendations to bring #AI language models into #oncology safely and effectively.
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
Stephen L. Chan discusses #CARES-009 and #SKYSCRAPER-14 phase 3 studies in #HCC at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
October 19, 2025 at 9:40 AM
Stephen L. Chan discusses #CARES-009 and #SKYSCRAPER-14 phase 3 studies in #HCC at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
CARES-009 phase 3 study of perioperative camrelizumab and rivoceranib for #HCC
#ESMO25 #ESMOAmbassadors
@myesmo.bsky.social
#ESMO25 #ESMOAmbassadors
@myesmo.bsky.social
October 19, 2025 at 9:22 AM
CARES-009 phase 3 study of perioperative camrelizumab and rivoceranib for #HCC
#ESMO25 #ESMOAmbassadors
@myesmo.bsky.social
#ESMO25 #ESMOAmbassadors
@myesmo.bsky.social
Richard Finn presents the results of phase 3 IMbrave152/SkYSCRAPER-14 study at #ESMO25
Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC
#ESMOAmbassadors @myesmo.bsky.social
Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC
#ESMOAmbassadors @myesmo.bsky.social
October 19, 2025 at 9:09 AM
Richard Finn presents the results of phase 3 IMbrave152/SkYSCRAPER-14 study at #ESMO25
Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC
#ESMOAmbassadors @myesmo.bsky.social
Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC
#ESMOAmbassadors @myesmo.bsky.social
HRS-4642 combined with chemo in advanced #KRAS-G12D mutant #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 19, 2025 at 8:40 AM
HRS-4642 combined with chemo in advanced #KRAS-G12D mutant #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Breaking the boundaries in pancreatic cancer #PDAC #surveillance #risk #liquidbiopsy #ctDNA #KRAS #noveltherapies
#ESMO25 #ESMOAmbassadors
@benwestphalen.bsky.social @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors
@benwestphalen.bsky.social @myesmo.bsky.social
October 18, 2025 at 3:24 PM
Breaking the boundaries in pancreatic cancer #PDAC #surveillance #risk #liquidbiopsy #ctDNA #KRAS #noveltherapies
#ESMO25 #ESMOAmbassadors
@benwestphalen.bsky.social @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors
@benwestphalen.bsky.social @myesmo.bsky.social
Reposted by Lorenza Rimassa
🤝 #Mentorship is key for the #CareerDevelopment of #OncologyProfessionals. #myESMOStory
Join us for a Mentor the Mentor session at #ESMO25!
📅 Saturday, 18 October 2025 | 11:30 – 12:30 | 📍 Erfurt Auditorium – CityCube A
🔗 https://ow.ly/PWWx50XbxHM
Join us for a Mentor the Mentor session at #ESMO25!
📅 Saturday, 18 October 2025 | 11:30 – 12:30 | 📍 Erfurt Auditorium – CityCube A
🔗 https://ow.ly/PWWx50XbxHM
October 17, 2025 at 2:45 PM
🤝 #Mentorship is key for the #CareerDevelopment of #OncologyProfessionals. #myESMOStory
Join us for a Mentor the Mentor session at #ESMO25!
📅 Saturday, 18 October 2025 | 11:30 – 12:30 | 📍 Erfurt Auditorium – CityCube A
🔗 https://ow.ly/PWWx50XbxHM
Join us for a Mentor the Mentor session at #ESMO25!
📅 Saturday, 18 October 2025 | 11:30 – 12:30 | 📍 Erfurt Auditorium – CityCube A
🔗 https://ow.ly/PWWx50XbxHM
Matteo Simonelli presents the results for MK-1084 monotherapy in patients with #KRAS #G12C-mutated advanced solid tumors enrolled in the #phase1 KANDLELIT-001 study at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 17, 2025 at 3:10 PM
Matteo Simonelli presents the results for MK-1084 monotherapy in patients with #KRAS #G12C-mutated advanced solid tumors enrolled in the #phase1 KANDLELIT-001 study at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social